Every dated change on the records linked to EBV-positive diffuse large B-cell lymphoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
In situ hybridisation for Epstein-Barr-encoded RNA on the biopsy. The European series that put the frequency at 3.1 per cent found that no morphological or immunohistochemical feature reliably identified the positive cases, and suggested that the stain be considered for every new diffuse large B-cell lymphoma in a person over 50, while leaving open whether routine testing can be recommended. Necrosis and CD30 expression are common in positive cases but neither is specific enough to select who to test.
WHO-HAEM5 renamed the entity EBV-positive diffuse large B-cell lymphoma, dropping the words not otherwise specified that the revised fourth edition had used in place of the earlier age qualifier, and stated that where it ends and lymphoma of immune deficiency and dysregulation begins is not yet settled.